158 related articles for article (PubMed ID: 31584491)
21. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
22. Whole-body
Ren YY; Li YC; Wu HB; Wang QS; Han YJ; Zhou WL; Li HS
Eur J Radiol; 2017 Apr; 89():200-207. PubMed ID: 28267540
[TBL] [Abstract][Full Text] [Related]
23. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis.
Kroese TE; Goense L; van Hillegersberg R; de Keizer B; Mook S; Ruurda JP; van Rossum PSN
Dis Esophagus; 2018 Dec; 31(12):. PubMed ID: 29917073
[TBL] [Abstract][Full Text] [Related]
24. Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study.
Quartuccio N; Evangelista L; Alongi P; Caobelli F; Altini C; Cistaro A; Lambertini A; Schiorlin I; Popescu CE; Linguanti F; Laudicella R; Scalorbi F; Di Pierro G; Asabella AN; Cuppari L; Margotti S; Lima GM; Scalisi S; Pacella S; Kokomani A; Ciaccio A; Sturiale L; Vento A; Cardile D; Baldari S; Panareo S; Fanti S; Rubini G; Schillaci O; Chiaravalloti A;
Nucl Med Commun; 2019 Aug; 40(8):808-814. PubMed ID: 31136534
[TBL] [Abstract][Full Text] [Related]
25. 18F-FDG PET/CT in primary brain lymphoma.
Albano D; Bosio G; Bertoli M; Giubbini R; Bertagna F
J Neurooncol; 2018 Feb; 136(3):577-583. PubMed ID: 29147860
[TBL] [Abstract][Full Text] [Related]
26. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
27. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
[TBL] [Abstract][Full Text] [Related]
28. Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer.
Baun C; Falch K; Gerke O; Hansen J; Nguyen T; Alavi A; Høilund-Carlsen PF; Hildebrandt MG
BMC Med Imaging; 2018 May; 18(1):11. PubMed ID: 29743027
[TBL] [Abstract][Full Text] [Related]
29. Whole-body [18F]FDG PET in the management of metastatic brain tumours.
Kim DG; Kim CY; Paek SH; Lee DS; Chung JK; Jung HW; Cho BK
Acta Neurochir (Wien); 1998; 140(7):665-73; discussion 673-4. PubMed ID: 9781280
[TBL] [Abstract][Full Text] [Related]
30. Incidence of Brain Metastases on Follow-up
Nia ES; Garland LL; Eshghi N; Nia BB; Avery RJ; Kuo PH
J Nucl Med Technol; 2017 Sep; 45(3):193-197. PubMed ID: 28705927
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
32. Detection of distant metastasis and prognostic prediction of recurrent salivary gland carcinomas using
Lee SH; Roh JL; Kim JS; Lee JH; Choi SH; Nam SY; Kim SY
Oral Dis; 2018 Sep; 24(6):940-947. PubMed ID: 29688610
[TBL] [Abstract][Full Text] [Related]
33. The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis.
King AD; Ma BB; Yau YY; Zee B; Leung SF; Wong JK; Kam MK; Ahuja AT; Chan AT
Br J Radiol; 2008 Apr; 81(964):291-8. PubMed ID: 18344274
[TBL] [Abstract][Full Text] [Related]
34. (68)Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma.
Khor LK; Loi HY; Sinha AK; Tong KT; Goh BC; Loh KS; Lu SJ
Head Neck; 2016 Apr; 38(4):E76-80. PubMed ID: 26275126
[TBL] [Abstract][Full Text] [Related]
35. Common malignant brain tumors: can 18F-FDG PET/CT aid in differentiation?
Purandare NC; Puranik A; Shah S; Agrawal A; Gupta T; Moiyadi A; Shetty P; Shridhar E; Jalali R; Rangarajan V
Nucl Med Commun; 2017 Dec; 38(12):1109-1116. PubMed ID: 28922334
[TBL] [Abstract][Full Text] [Related]
36. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
Trybek T; Kowalska A; Lesiak J; Młynarczyk J
Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic and prognostic value of 18F-FDG PET/CT imaging in suspected recurrence of male breast cancer.
Vadi SK; Mittal BR; Sood A; Singh G; Bal A; Parihar AS; Bhattacharya A; Basher RK; Kapoor R
Nucl Med Commun; 2019 Jan; 40(1):63-72. PubMed ID: 30312217
[TBL] [Abstract][Full Text] [Related]
38. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Aquino SL; Fischman AJ
Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
[TBL] [Abstract][Full Text] [Related]
39. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer.
Uesaka D; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Fujibayashi Y; Okazawa H
J Nucl Med; 2008 Oct; 49(10):1606-12. PubMed ID: 18794269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]